Connor, Clark & Lunn Investment Management Ltd.

Position in REPL — Replimune Group, Inc.

CIK 1596800 VANCOUVER, A1

Position in REPL

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$664,861

-$635,946 QoQ

Shares Held

86,910

-19.1% QoQ

Ownership

0.104%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2022

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. REPL ranks #77 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$664,861	86,910	-19.1%	Shares	Sole	2026-05-11
2024-12-31	$1,300,807	107,416	-16.2%	Shares	Sole	2025-02-10
2024-09-30	$1,405,159	128,208	+25.4%	Shares	Sole	2024-11-08
2024-06-30	$920,421	102,269	-51.9%	Shares	Sole	2024-08-09
2024-03-31	$1,737,375	212,653	+17.9%	Shares	Sole	2024-05-09
2023-12-31	$1,521,126	180,442	+118.8%	Shares	Sole	2024-02-09
2023-09-30	$1,411,164	82,476	-8.1%	Shares	Sole	2023-11-13
2023-06-30	$2,084,273	89,762	+311.8%	Shares	Sole	2023-08-10
2023-03-31	$384,988	21,800	-37.7%	Shares	Sole	2023-05-10
2022-12-31	$951,238	34,972	+19.9%	Shares	Sole	2023-02-10
2022-09-30	$503,765	29,170	+172.2%	Shares	Sole	2022-11-10
2022-06-30	$187,350	10,718	—	Shares	Sole	2022-08-05
No filing history on record for this holder in this stock.